Effects of the GABA-reuptake Inhibitor Tiagabine on Panic and Anxiety in Patients with Panic Disorder

Abstract

Introduction: There is evidence that a decreased GABAergic tone plays a role in the pathophysiology of panic disorder (PD). Selective GABAergic treatment has been suggested as a new therapeutic strategy in PD. In this pilot-study anxiolytic effects of the GABA reuptake inhibitor tiagabine (TGB) were investigated in PD.

Methods: A total of 19 patients were treated with TGB (n=10) or placebo (n=9) for 4 weeks. PAS, HAM-A, and CGI ratings were administered every week. To further assess specific antipanic activity, panic challenges with CCK-4 were carried out in single subjects.

Results: Although there was a significant reduction of clinical rating scores over time, no differences were detected between the groups. However, during challenge experiments TGB treated subjects showed decreased sensitivity to CCK-4.

Discussion: Whereas tiagabine did not show beneficial effects on clinical symptoms in PD compared to placebo, results of challenge experiments suggest effects of TGB on sensitivity to experimentally induced panic.

References

• 1 Ballenger JC, Burrows GD, DuPont  Jr  RL. et al . Alprazolam in panic disorder and agoraphobia: Results from a multicenter trial. I. Efficacy in short-term treatment.  Archives of General Psychiatry. 1988;  45 413-422
• 2 Bandelow B, Stein DJ, Dolberg OT. et al . Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo.  Pharmacopsychiatry. 2007;  40 152-156
• 3 Bandelow B. Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale.  Int Clin Psychopharmacol. 1995;  10 73-81
• 4 Bradwejn J, Koszycki D. Cholecystokinin and panic disorder: past and future clinical research strategies.  Scand J Clin Lab Invest Suppl. 2001;  19-27
• 5 Cameron OG, Huang GC, Nichols T. et al . Reduced gamma-aminobutyric acid (A)-benzodiazepine binding sites in insular cortex of individuals with panic disorder.  Archives of General Psychiatry. 2007;  64 793-800
• 6 Dillon DJ, Gorman JM, Liebowitz MR. et al . Measurement of lactate-induced panic and anxiety.  Psychiatry Res. 1987;  20 97-105
• 7 Goddard AW, Mason GF, Almai A. et al . Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy.  Archives of General Psychiatry. 2001;  58 556-561
• 8 Hamilton M. The assessment of anxiety states by rating.  Br J Med Psychol. 1959;  32 50-55
• 9 Hasler G, Nugent AC, Carlson PJ. et al . Altered cerebral gamma-aminobutyric acid type A-benzodiazepine receptor binding in panic disorder determined by [11C]flumazenil positron emission tomography.  Arch Gen Psychiatry. 2008;  65 1166-1175
• 10 Meldrum BS. Update on the mechanism of action of antiepileptic drugs.  Epilepsia. 1996;  37 ((Suppl 6)) S4-11
• 11 Pistovcakova J, Dostalek M, Sulcova A. et al . Tiagabine treatment is associated with neurochemical, immune and behavioural alterations in the olfactory bulbectomized rat model of depression.  Pharmacopsychiatry. 2008;  41 54-59
• 12 Pollack MH, Roy-Byrne PP, Van AM. et al . The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: Results of a placebo-controlled study.  Journal of Clinical Psychiatry. 2005;  66 1401-1408
• 13 Sayin U, Cengiz S, Altug T. Vigabatrin as an anticonvulsant against pentylenetetrazol seizures.  Pharmacology Research. 1993;  28 325-331
• 14 Sayin U, Purali N, Ozkan T. et al . Vigabatrin has an anxiolytic effect in the elevated plus-maze test of anxiety.  Pharmacology Biochemistry and Behavior. 1992;  43 529-535
• 15 Schmitt U, Hiemke C. Effects of GABA-transporter (GAT) inhibitors on rat behaviour in open-field and elevated plus-maze.  Behavioral Pharmacology. 1999;  10 131-137
• 16 Schmitt U, Luddens H, Hiemke C. Anxiolytic-like effects of acute and chronic GABA transporter inhibition in rats.  Journal of Neural Transmission. 2002;  109 871-880
• 17 Sheehan DV, Sheehan KH, Raj BA. et al . Psychopharmacol Bull.  2007;  40 32-40
• 18 Sherif F, Harro J, el-Hwuegi A. et al . Anxiolytic-like effect of the GABA-transaminase inhibitor vigabatrin (gamma-vinyl GABA) on rat exploratory activity.  Pharmacology Biochemistry and Behavior. 1994;  49 801-805
• 19 Sherif F, Oreland L. Effect of the GABA-transaminase inhibitor vigabatrin on exploratory behaviour in socially isolated rats.  Behavioral Brain Research. 1995;  72 135-140
• 20 Shlik J, Aluoja A, Vasar V. et al . Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder.  J Psychiatry Neurosci. 1997;  22 332-340
• 21 van Megen H, Westenberg HG, den Boer J. et al . Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK- 4 induced panic attacks.  Psychopharmacology. 1997;  129 357-364
• 22 Zwanzger P, Baghai T, Boerner RJ. et al . Anxiolytic effects of vigabatrin in panic disorder.  J Clin Psychopharmacol. 2001;  21 539-540
• 23 Zwanzger P, Baghai TC, Schuele C. et al . Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers.  Neuropsychopharmacology. 2001;  25 699-703
• 24 Zwanzger P, Eser D, Aicher S. et al . Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenal-axis activity: A placebo-controlled study.  Neuropsychopharmacology. 2003;  28 979-984
• 25 Zwanzger P, Baghai TC, Schule C. et al . Tiagabine improves panic and agoraphobia in panic disorder patients.  Journal of Clinical Psychiatry. 2001;  62 656-657
• 26 Zwanzger P, Eser D, Padberg F. et al . Effects of tiagabine on cholecystokinin-tetrapeptide (CCK-4)-induced anxiety in healthy volunteers.  Depression and Anxiety. 2003;  18 140-143
• 27 Zwanzger P, Rupprecht R. Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder.  Journal of Psychiatry and Neuroscience. 2005;  30 167-175

Correspondence